Compare Globus Medical Inc. Class A Common Stock (GMED) vs International Business Machines Corp (IBM) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

IBM trades at $227.88, up 0.38% with a bearish technical signal despite recent positive momentum. The company shows strong fundamentals with 2025 revenue of $67.54B and net income of $10.59B, representing a 15.52% margin. Recent earnings beat expectations in two of the last three quarters, while Q3 2026 results are pending. Analyst consensus is mixed with 47% buy ratings and a $255.50 price target, suggesting 12% upside potential from current levels.

IBM presents a balanced opportunity with solid profitability and AI consulting growth offset by cyclical mainframe weakness and negative cash flow trends. The stock's current valuation at 20.5x P/E appears reasonable given the company's pivot to high-margin hybrid cloud and AI services. Key risks include execution challenges in the AI transition and competitive pressures in the consulting space.